

(19)



(11)

EP 2 117 583 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention of the grant of the patent:
22.05.2013 Bulletin 2013/21

(51) Int Cl.:
A61K 38/19 (2006.01) A61K 31/70 (2006.01)
A61P 35/00 (2006.01)

(21) Application number: **08716968.6**

(86) International application number:
PCT/EP2008/052055

(22) Date of filing: **20.02.2008**

(87) International publication number:
WO 2008/101951 (28.08.2008 Gazette 2008/35)

(54) **Combination therapy using TNF and alpha-galactosyl ceramide**

Kombinationstherapie mit TNF und alpha-Galactosylceramid

Thérapie combinatoire par TNF et alpha-galactosylcéramide

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

(30) Priority: **21.02.2007 EP 07102787**

(43) Date of publication of application:
18.11.2009 Bulletin 2009/47

(73) Proprietors:
• **VIB VZW**
9052 Gent (BE)
• **Universiteit Gent**
9000 Gent (BE)

(72) Inventors:
• **BROUCKAERT, Peter**
B-9000 Gent (BE)
• **ELEWAUT, Dirk**
B-9070 Heusden (BE)
• **HUYGHE, Leander**
B-8700 Aarsele (BE)

(56) References cited:

- **NAKUI ET AL: "Potentiation of antitumor effect of NKT cell ligand, alpha-galactosylceramide by combination with IL-12 on lung metastasis of malignant melanoma cells" CLINICAL & EXPERIMENTAL METASTASIS, vol. 18, 2000, pages 147-153, XP019235487**
- **INUI ET AL: "Neutralization of tumor necrosis factor abrogates hepatic failure induced by alpha-galactosylceramide without attenuating its antitumor effect in aged mice" JOURNAL OF HEPATOLOGY, vol. 43, 2005, pages 670-678, XP005058388**
- **METELITSA ET AL: "Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells" LEUKEMIA, vol. 17, 2003, pages 1068-1077, XP002484797**
- **NISHI ET AL: "Synergistic effect of KRN7000 with interleukin-15, -7, and -2 on the expansion of human V-alpha-24(+)-V-beta-11(+) T cells in vitro" HUMAN IMMUNOLOGY, vol. 61, 2000, pages 357-365, XP001146058**

EP 2 117 583 B1

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).